Milecki Tomasz, Antczak Andrzej, Kwias Zbigniew, Milecki Piotr
Department and Clinic of Urology and Urologic Oncology, Poznan University of Medical Science, Poznan, Poland.
Chair and Department of Electroradiology, Poznan University of Medical Sciences, Poznan, Poland ; Department of Radiotherapy, Greater Poland Cancer Centre, Poznan, Poland.
Contemp Oncol (Pozn). 2015;19(1):1-5. doi: 10.5114/wo.2015.50010. Epub 2015 Mar 26.
In recent years, significant development in the treatment of prostate cancer has taken place. One of the most documented methods of treatment in patients characterised by a high risk of progression is a combination of radiotherapy (RT) with long-term hormone therapy (HT). In this group of patients, neither RT alone nor HT alone allows satisfactory outcomes to be achieved, and therefore as monotherapy they are not recommended as optimal methods of treatment. In this review, we summarise arguments for combining radiotherapy with hormonal therapy in high-risk prostate cancer, with an emphasis on the results of phase III trials.
近年来，前列腺癌的治疗取得了重大进展。对于具有高进展风险特征的患者，记录最详尽的治疗方法之一是放疗（RT）与长期激素治疗（HT）相结合。在这组患者中，单独使用RT或单独使用HT都无法取得令人满意的结果，因此作为单一疗法，它们不被推荐为最佳治疗方法。在本综述中，我们总结了高风险前列腺癌放疗与激素治疗联合应用的依据，重点是III期试验的结果。
